Navigation Links
More Evidence Shows Hormone Therapy May Increase Breast Cancer Risk
Date:4/1/2013

By Kathleen Doheny
HealthDay Reporter

FRIDAY, March 29 (HealthDay News) -- Women who take hormone therapy that includes estrogen and progestin are at increased risk of developing breast cancer and dying from it, especially if they start taking the therapy just as menopause begins, a new analysis confirms.

Researchers followed nearly 42,000 women, all of whom were past menopause, for an average of more than 11 years. Of those, more than 25,000 did not use hormone therapy and more than 16,000 took estrogen and progestin, also called combined hormone therapy. For this analysis, the researchers did not include estrogen-only therapy, used by women who have had a hysterectomy.

At the end of the follow-up period, more than 2,200 of the women were found to have breast cancer. Compared to non-users, those who took combined therapy were more likely to have breast cancer, said Dr. Rowan Chlebowski, a medical oncologist at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center. Chlebowski led the study, which was published in the March 29 issue of the Journal of the National Cancer Institute.

The link has been found in other studies, but Chlebowski also found the risk was greatest among those who took the hormones closest to menopause. "Women starting within months of menopause had about a threefold greater risk than women starting 10 years after menopause," Chlebowski said.

For the new analysis, Chlebowksi looked at results from the Women's Health Initiative observational study. He compared the findings with those from the Women's Health Initiative randomized clinical trial, in which women were assigned to different treatments.

The Women's Health Initiative included four clinical trials and an observational study. Women were all past menopause and were aged 50 to 79.

Chlebowski said he did the new analysis to resolve what he saw as unanswered questions. In the trial, only about one-third, or 5,000, of the women were in their 50s when they started the study. As that is the typical age for menopause to start, about two-thirds of the women in the trial were in their 60s or beyond, so began to take hormones several years after menopause.

Chlebowski set out to see if the link between breast cancer risk and combined hormone therapy use was influenced by earlier use of hormones.

"We had a substantial number closer to menopause than the clinical trial of [the Women's Health Initiative]," he said.

He found, however, that not only was the risk of breast cancer still increased, but it also increased even more if the women were closer to menopause when they began to take the hormones.

He speculated that women who start the hormone therapy close to menopause still have circulating levels of estrogen high enough to make them exceed some threshold, beyond which it may become hazardous.

Progestin is thought to play a role, too, he added.

Although others have thought that the breast cancers linked with combined hormone therapy are often ones with a somewhat better outlook -- another question Chlebowski thought needed more study -- he did not find that in his new analysis.

The new analysis reinforces the finding that combination hormone therapy is linked with higher breast cancer risk, said Dr. Joanne Mortimer, director of Women's Cancer Programs at the City of Hope Comprehensive Cancer Center in Duarte, Calif.

Although previous research has found some good effects of hormone therapy on the heart, she and Chlebowski said that has to be weighed against the breast cancer risk found in much other research.

The new analysis also suggests that "the time of starting hormone therapy really matters," Mortimer said. Although the analysis found an association between the two, it did not prove a cause-and-effect link.

Mortimer and Chlebowski agreed that women need to discuss the pros and cons of hormone therapy during menopause with their doctors.

Women should seriously consider whether their symptoms, such as hot flashes and night sweats, are limiting enough to warrant taking hormones, Chlebowski said. Although some women are severely bothered by symptoms, he said, others may be less bothered and can avoid hormone therapy.

More information

To learn more about hormone therapy after menopause, visit the American Cancer Society.

SOURCES: Rowan Chlebowski, M.D., medical oncologist, Los Angeles Biomedical Research Institute, Harbor-UCLA Medical Center, Torrance, Calif.; Joanne Mortimer, M.D., director, Women's Cancer Programs, City of Hope Comprehensive Cancer Center, Duarte, Calif.; March 29, 2013, Journal of the National Cancer Institute


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. DrugRisk Update: Evidence Submitted in Actos Lawsuit Suggests Drug Maker Knew of Cancer Risks
2. New Analysis Says Evidence Lacking for HRT-Breast Cancer Link
3. Evidence supports blocking immune response to enhance viral therapy against solid tumors
4. More Evidence Whooping Cough Protection Wanes
5. First evidence that obesity gene is risk factor for melanoma
6. More Evidence That Smoking Raises Breast Cancer Risk
7. Evidence shows concussions require long-term follow-up for players
8. Review: Few effective, evidence-based interventions for children exposed to traumatic events
9. Reassuring evidence: Anticancer drug does not accelerate tumor growth after treatment ends
10. JSCM publishes issue on NIDRR-funded project on practice-based evidence in SCI rehabilitation
11. Review Finds No Evidence Alzheimers, Parkinsons Are Infectious
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
More Evidence Shows Hormone Therapy May Increase Breast Cancer Risk
(Date:4/28/2017)... ... April 28, 2017 , ... Woolsy Corporation ... supplements, through its Nova Skin Sciences division, recently announced the launch of Allumière ... with the power of an anti-aging concentrate. , Anogeissus Leiocarpa Bark ...
(Date:4/28/2017)... ... April 28, 2017 , ... Semrock’s highly popular SearchLight ... online modeling resource for fluorescence microscopists and optical system designers, enabling The Right ... years spanning the globe, SearchLight has become a tremendously popular tool for the ...
(Date:4/27/2017)... ... April 27, 2017 , ... The Incentive Research Foundation ... A Nudge Guide," a groundbreaking analysis of how behavioral economics can be applied ... immediately to IRR programs, the report highlights proven behavioral economics approaches and the ...
(Date:4/27/2017)... ... April 27, 2017 , ... The American Brain Foundation ... Leadership in Neurology Award (PLINA). The couple joins a prestigious list of past ... Walter Mondale, actor Michael J. Fox and former U.S. Attorney General Janet Reno. ...
(Date:4/27/2017)... ... ... Goodcents Deli Fresh Subs announced a franchise expansion agreement today including three new ... first new location will open at the corner of 27th and Randolph in Lincoln, ... this fall. And the third location is in the process of being identified. ...
Breaking Medicine News(10 mins):
(Date:4/24/2017)... 24, 2017 Solentim, the developer of ... addition of a major new product line called ... The VIPS has been developed for automatically seeding ... as part of the process to generate clonally-derived ... and more reliable solution when compared to traditional ...
(Date:4/20/2017)... DUBLIN , April 20, 2017 ... the "Global Biosimilar Pipeline and Market Prospects: Addressing ... report to their offering. ... "Global Biosimilar Pipeline and Market ... by Design" provides an in-depth assessment of the current ...
(Date:4/20/2017)... AMSTERDAM , April 20, 2017  AbbVie ... that 99 percent (n=145/146) of chronic hepatitis C ... 4, 5 or 6 and compensated cirrhosis (Child-Pugh ... post-treatment (SVR 12 ) with its investigational, pan-genotypic ... rates were seen following 12 weeks of ...
Breaking Medicine Technology: